tiprankstipranks
Scinai Immunotherapeutics’ Strategic Growth and Drug Advancements
Company Announcements

Scinai Immunotherapeutics’ Strategic Growth and Drug Advancements

Scinai Immunotherapeutics (SCNI) has released an update.

Don't Miss our Black Friday Offers:

Scinai Immunotherapeutics has announced a promising Q2 2024 with a strategic restructuring of a $29 million EIB loan into equity, potentially resolving its Nasdaq compliance issues by late August. The company is also confident in its CDMO business, anticipating revenue growth following targeted marketing efforts and successful biotech collaborations. Additionally, Scinai reports advancements in its NanoAb drug development, with positive regulatory feedback and preparation for a Phase 1/2a clinical trial in plaque psoriasis.

For further insights into SCNI stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskScinai Immunotherapeutics Gains Shareholder Confidence
TipRanks Auto-Generated NewsdeskScinai Immunotherapeutics to Hold Annual Shareholder Meeting
TipRanks Auto-Generated NewsdeskScinai Immunotherapeutics Licenses Global Rights
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App